Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Innoviva stock

Own Innoviva stock in just a few minutes.

Innoviva, Inc is a biotechnology business based in the US. Innoviva shares (INVA) are listed on the NASDAQ and all prices are listed in US Dollars. Innoviva employs 5 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Innoviva

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INVA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Innoviva share price

Use our graph to track the performance of INVA stocks over time.

Innoviva shares at a glance

Information last updated 2021-04-30.
52-week range$9.21 - $15.62
50-day moving average $11.93
200-day moving average $11.54
Wall St. target price$10.00
PE ratio 5.1455
Dividend yield $0 (0%)
Earnings per share (TTM) $2.27

Buy Innoviva shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Innoviva stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Innoviva under- or over-valued?

Valuing Innoviva stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innoviva's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Innoviva's P/E ratio

Innoviva's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Innoviva shares trade at around 5x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Innoviva's PEG ratio

Innoviva's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.24. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Innoviva's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Innoviva's EBITDA

Innoviva's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $326.2 million.

The EBITDA is a measure of a Innoviva's overall financial performance and is widely used to measure a its profitability.

Innoviva financials

Revenue TTM $343.6 million
Operating margin TTM 94.92%
Gross profit TTM $335 million
Return on assets TTM 21.73%
Return on equity TTM 58.87%
Profit margin 73.65%
Book value $6.26
Market capitalisation $1.2 billion

TTM: trailing 12 months

Shorting Innoviva shares

There are currently 8.7 million Innoviva shares held short by investors – that's known as Innoviva's "short interest". This figure is 0.8% down from 8.8 million last month.

There are a few different ways that this level of interest in shorting Innoviva shares can be evaluated.

Innoviva's "short interest ratio" (SIR)

Innoviva's "short interest ratio" (SIR) is the quantity of Innoviva shares currently shorted divided by the average quantity of Innoviva shares traded daily (recently around 505349.39271255). Innoviva's SIR currently stands at 17.29. In other words for every 100,000 Innoviva shares traded daily on the market, roughly 17290 shares are currently held short.

However Innoviva's short interest can also be evaluated against the total number of Innoviva shares, or, against the total number of tradable Innoviva shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Innoviva's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Innoviva shares in existence, roughly 90 shares are currently held short) or 0.1508% of the tradable shares (for every 100,000 tradable Innoviva shares, roughly 151 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Innoviva.

Find out more about how you can short Innoviva stock.

Innoviva share dividends

We're not expecting Innoviva to pay a dividend over the next 12 months.

Have Innoviva's shares ever split?

Innoviva's shares were split on a 1241:1000 basis on 2 June 2014. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1241 shares. This wouldn't directly have changed the overall worth of your Innoviva shares – just the quantity. However, indirectly, the new 19.4% lower share price could have impacted the market appetite for Innoviva shares which in turn could have impacted Innoviva's share price.

Innoviva share price volatility

Over the last 12 months, Innoviva's shares have ranged in value from as little as $9.21 up to $15.62. A popular way to gauge a stock's volatility is its "beta".

INVA.US volatility(beta: 0.64)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innoviva's is 0.6387. This would suggest that Innoviva's shares are less volatile than average (for this exchange).

Innoviva overview

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site